Company Showcase

PROMOTE A HEALTHIER LIFE FOR HUMANKIND THROUGH ADVANCEMENTS IN SCIENCE

...

Hengrui Medicine - Company Details

...

API Product List

...

Finished Dosage Form List

Posted By

Dong Wei

Director of International Business Division

[email protected]

     Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. In 1997, it was restructured into a joint-stock company. In 2000 Hengrui was listed on Shanghai Stock Exchange under stock code 600276. The company ranks top 30 worldwide in pharmaceuticals industry by a market capitalization of over 55 billion USD, and is home to more than 21,900 employees worldwide. Hengrui stands out as a front-runner in cancer drugs, contrast agents, and surgical medicines. Hengrui fully owns 8 manufacturing facilities for small and large molecules as well as medical devices. All facilities are approved and audited by NMPA, most also approved by US FDA, EDQM, TGA, and PMDA. We have 11 R&D centers where over 3,000 research staff work on hundreds of therapeutic candidates, many of which may become first-in-class or best-in-class products. Hengrui conducts most of its clinical trials using in-house capabilities that cover medical, trial operations, data management, statistics, and regulatory. This allows us to better control speed and quality. Embracing the spirit of “Honesty and Trustworthiness, Quality First” as a business principle, Hengrui leads the Chinese markets for anti-cancer drugs, surgical anesthetics, specialized infusions, and contrast agents. To date, Hengrui has 10+ products approved in Europe, US, and Japan, covering injectables, oral formulations, and inhalational anesthetics, and has achieved remarkable sales in those markets. Pursuing the concept of “Excelling in Science, Enhancing Life”, Hengrui sees its future as a Chinese multi-national pharmaceutical corporation, and continuously strives for innovation, progress, and achievement of new breakthrough in the healthcare industry. Contact: Mr Dong Wei
Email: [email protected], [email protected]

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)

Primary business activity

Manufacturer/Innovator

Meet us at

CPhI Discover

Online event

May 17 - 28, 2021


View Our Exhibitor Profile

Meet us at

CPhI South East Asia 2021

Hall 7-8, IMPACT, Muang Thong Thani, Thailand

4 - 6 August 2021

Book a meeting
View Our Exhibitor Profile

Meet us at

CPhI Worldwide 2021

Fiera Milano, Milan, Italy

9-11 November 2021

Book a meeting
View Our Exhibitor Profile

Contact information

Address

Telephone

Website

View All Contact Info

Our Team

BD Manager

BD director

DONG WEI

Director of International Business Division

View Team Details

Top Products

Sevoflurane Inhalation Anesthetic

Sevoflurane Inhalation Anesthetic

Jiangsu Hengrui Medicine Co., Ltd.

Request Info
Desflurane for inhalation

Desflurane for inhalation

Jiangsu Hengrui Medicine Co., Ltd.

Request Info
Dexmedetomidine HCl Injection

Dexmedetomidine HCl Injection

Jiangsu Hengrui Medicine Co., Ltd.

Request Info
Atracurium Besylate

Atracurium Besylate

Jiangsu Hengrui Medicine Co., Ltd.

Request Info

Our Resources

Categories affiliated with Jiangsu Hengrui Medicine Co., Ltd.